Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models

Clinical Cancer Research

Volumn 16, Issue 4, 2010, Pages 1170-1178

  Watanabe, Kazushi ^a   Tanimura, Susumu ^a   Uchiyama, Aya ^a   Sakamoto, Toshiaki ^a   Kawabata, Takumi ^a   Ozaki, Kei Ichi ^a   Kohno, Michiaki ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; NAVELBINE; SOBLIDOTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER MODEL; CANCER PATIENT; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG MEGADOSE; HUMAN; HUMAN CELL; MICROTUBULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HT29 CELLS; HUMANS; MAP KINASE KINASE KINASES; MICE; MICE, INBRED BALB C; OLIGOPEPTIDES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TUBULIN MODULATORS; VINBLASTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 76749100341     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2482     Document Type: Article

References (29)

1. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998;74:49-139.
2. Oka H, Chatani Y, Hoshino R, et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 1995;55:4182-7.
3. Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999;18:813-22.
4. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54.
5. Downward J. Targeting RAS signaling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22.
6. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004;5:875-85.
7. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47.
8. Kohno M, Pouyssegur J. Targeting the ERK pathway in cancer therapy. Ann Med 2006;38:200-11.
9. Kip1. J Biol Chem 2001;276:2686-92.
10. Tanimura S, Asato K, Fujishiro S, Kohno M. Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: down-regulation of matrix metalloproteinase-3/-9/-14 and CD44. Biochem Biophys Res Commun 2003;304:801-6.
11. Tanimura S, Uchiyama A, Watanabe K, et al. Blockade of constitutively activated ERK signaling enhances cytotoxicity of microtubuledestabilizing agents in tumor cells. Biochem Biophys Res Commun 2009;378:650-5.
12. Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007;13: 1576-83.
13. Rinehart J, Adjei AA, LoRusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004;22: 4456-62.
14. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26:2139-46.
15. Hambley TW. Is anticancer drug development heading in the right direction? Cancer Res 2009;69:1259-61.
16. Dent P, Grant S. Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action. Clin Cancer Res 2001;7:775-83.
17. MacKeigan JP, Collins TS, Ting JP. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 2000;275:38953-6.
18. McDaid HM, Lopez-Barcons L, Grossman A, et al. Enhancement of the therapeutic efficacy of Taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res 2005;65:2854-60.
19. Davies BR, Logie A, McKay JS, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007;6: 2209-19.
20. Haass NK, Sproesser K, Nguyen TK, et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induced growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 2008;14:230-9.
21. Fujiwara Y, Hosokawa Y, Watanabe K, Tanimura S, Ozaki K, Kohno M. Blockade of the phosphatidylinositol-3-kinase-Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated. Mol Cancer Ther 2007;6:1133-42.
22. Ogawa T, Mimura Y, Isowa K, et al. An antimicrotubule agent, TZT-1027, does not induce neuropathologic alterations which are detected after administration of vincristine or paclitaxel in animal models. Toxicol Lett 2001;121:97-106.
23. Hohneker JA. A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 1994;5:42-7.
24. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B958. Cancer Res 1995;55:5310-4.
25. Sebolt-Leopold JS, Dudley DH, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999;5:810-6.
26. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol 2002;20:55-72.
27. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004;23:2825-37.
28. Tamemoto H, Kadowaki T, Tobe K, et al. Biphasic activation of two mitogen-activated protein kinases during the cell cycle in mammalian cells. J Biol Chem 1992;267:20293-7.
29. Mhaidat NM, Thorne RF, Zhang XD, et al. Regulation of docetaxel-induced apoptosis of human melanoma cells by different isoforms of protein kinase C. Mol Cancer Res 2007;5:1073-81.